Human Continuum is developing a platform of exosome-based therapeutics and diagnostics spanning longevity, orthopedics, aesthetics, and dermatology. Its lead program is designed to investigate regenerative signaling pathways with the aim of evaluating effects on inflammatory biomarkers. In parallel the company is advancing topical exosome dermatologic formulations, a point-of-care exosome diagnostic technology, and an exosomal biomarker panel for longitudinal monitoring of orthopedic diseases. The company recently closed a $5.13 million seed financing to accelerate these development efforts. Management stated the capital will be used to expand the technical team and strengthen research and development capabilities. The company positions its approach as harnessing regenerative signals released by platelets without using the cells themselves to provide a scalable, standardized regenerative-medicine modality.

Total raised

$5M

Funding rounds

1

Latest round

Seed

Latest activity

Jun 2026